Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProQR Therapeutics NV PRQR

Healthcare Biotechnology
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is... see more

Recent & Breaking News (NDAQ:PRQR)

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

GlobeNewswire December 8, 2023

ProQR Announces Third Quarter 2023 Operating and Financial Results

GlobeNewswire November 7, 2023

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

GlobeNewswire November 6, 2023

ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

GlobeNewswire September 28, 2023

ProQR Therapeutics Provides Update on Ophthalmic Assets

GlobeNewswire September 27, 2023

ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 7, 2023

ProQR Announces Second Quarter 2023 Operating and Financial Results

GlobeNewswire August 3, 2023

ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic Assets

GlobeNewswire August 1, 2023

ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

GlobeNewswire July 6, 2023

ProQR Announces First Quarter 2023 Operating and Financial Results

GlobeNewswire May 16, 2023

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

GlobeNewswire May 9, 2023

ProQR Announces Upcoming Investor Conferences in April and May

GlobeNewswire April 20, 2023

ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023

GlobeNewswire April 18, 2023

ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

GlobeNewswire March 29, 2023

ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing

GlobeNewswire March 14, 2023

ProQR to Present at Upcoming Scientific and Industry Conferences

GlobeNewswire March 7, 2023

ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023

GlobeNewswire February 28, 2023

ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform

GlobeNewswire December 22, 2022

Lilly and ProQR to Expand RNA Editing Collaboration

GlobeNewswire December 22, 2022

ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022

GlobeNewswire November 14, 2022